Trial
NCT01127633
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Alzheimer's Disease
Intervention
Solanezumab
Why stopped
Solanezumab did not meet the primary endpoint in study H8A-MC-LZAX.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-10-08